Abstract
The ascent of polypharmacology in drug development has many implications for disease therapy, most notably in the efforts of drug discovery, drug repositioning, precision medicine and combination therapy. The single- target approach to drug development has encountered difficulties in predicting drugs that are both clinically efficacious and avoid toxicity. By contrast, polypharmacology offers the possibility of a controlled distribution of effects on a biological system. This review addresses possibilities and bottlenecks in the efficient computational application of polypharmacology. The two major areas we address are the discovery and prediction of multiple protein targets using the tools of computer-aided drug design, and the use of these protein targets in predicting therapeutic potential in the context of biological networks. The successful application of polypharmacology to systems biology and pharmacology has the potential to markedly accelerate the pace of development of novel therapies for multiple diseases, and has implications for the intellectual property landscape, likely requiring targeted changes in patent law.
Keywords: Polypharmacology, systems biology, docking, computer aided drug design, natural language processing.
Current Pharmaceutical Design
Title:Harnessing Polypharmacology with Computer-Aided Drug Design and Systems Biology
Volume: 22 Issue: 21
Author(s): Henri Wathieu, Naiem T. Issa, Stephen W. Byers and Sivanesan Dakshanamurthy
Affiliation:
Keywords: Polypharmacology, systems biology, docking, computer aided drug design, natural language processing.
Abstract: The ascent of polypharmacology in drug development has many implications for disease therapy, most notably in the efforts of drug discovery, drug repositioning, precision medicine and combination therapy. The single- target approach to drug development has encountered difficulties in predicting drugs that are both clinically efficacious and avoid toxicity. By contrast, polypharmacology offers the possibility of a controlled distribution of effects on a biological system. This review addresses possibilities and bottlenecks in the efficient computational application of polypharmacology. The two major areas we address are the discovery and prediction of multiple protein targets using the tools of computer-aided drug design, and the use of these protein targets in predicting therapeutic potential in the context of biological networks. The successful application of polypharmacology to systems biology and pharmacology has the potential to markedly accelerate the pace of development of novel therapies for multiple diseases, and has implications for the intellectual property landscape, likely requiring targeted changes in patent law.
Export Options
About this article
Cite this article as:
Wathieu Henri, T. Issa Naiem, W. Byers Stephen and Dakshanamurthy Sivanesan, Harnessing Polypharmacology with Computer-Aided Drug Design and Systems Biology, Current Pharmaceutical Design 2016; 22 (21) . https://dx.doi.org/10.2174/1381612822666160224141930
DOI https://dx.doi.org/10.2174/1381612822666160224141930 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Smoking, Estradiol Metabolism and Hormone Replacement Therapy
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Endothelial Function in Renal Transplant Recipients is Associated with Circulating Nitric Oxide, ACE Inhibitor Use and Time After Transplantation
Vascular Disease Prevention (Discontinued) Endothelial Therapy of Atherosclerosis and its Risk Factors
Current Vascular Pharmacology Non-enzymatic Glycation of Almond Cystatin Leads to Conformational Changes and Altered Activity
Protein & Peptide Letters Editorial: Cures of Vascular Disease - The State
Current Vascular Pharmacology Coarse Classification to Region-Scalable Refining for White Matter Lesions Segmentation in Multi-Channel MRI
CNS & Neurological Disorders - Drug Targets Withdrawal Notice: Reconnoitering the Role of Endothelin in Obesity
Current Pharmaceutical Design Inflammatory Cytokines and Atherosclerosis Possible Application for the Gene Therapy
Vascular Disease Prevention (Discontinued) Imaging Features of Thoracic Manifestations of Behçet’s Disease: Beyond Pulmonary Artery Involvement
Current Medical Imaging Non-Invasive Diagnostic Tools for Investigating Endothelial Dysfunction
Current Pharmaceutical Design Strict Adherence to Guidelines in Decision Making for Coronary Angiography in Patients Who have Survived a Q Wave Myocardial Infarction; 2-Year Outcome in a Greek Population
Vascular Disease Prevention (Discontinued) Biological Consequences of Dysfunctional HDL
Current Medicinal Chemistry Utilization of Microfluidics for the Preparation of Polymeric Nanoparticles for the Antioxidant Rutin: A Comparison with Bulk Production
Pharmaceutical Nanotechnology Predictive Factors of follow-up Non-attendance and Mortality Among Adults with Type 2 Diabetes Mellitus- an Analysis of the Malaysian Diabetes Registry 2009
Current Diabetes Reviews Coagulation Factor XIIIA (F13A1): Novel Perspectives in Treatment and Pharmacogenetics
Current Pharmaceutical Design Gender Differences in Aminoglycoside Induced Nephrotoxicity: A Prospective, Hospital - Based Study
Current Clinical Pharmacology Choice of Antihypertensive Treatment in Subjects with Pre-Diabetes. Is There a Dream After the Navigator
Current Vascular Pharmacology Sympathetic Overactivity in Patients with Chronic Renal Failure - The Culprit of Increased Cardiovascular Mortality?
Current Hypertension Reviews Arterial Stiffness and Cardiovascular Drugs
Current Pharmaceutical Design Interleukins Involved in Inflammatory Bowel Disease as New Therapeutic Targets
Current Immunology Reviews (Discontinued)